Log in

NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Forecast & News

$3.19
0.00 (0.00 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$3.06
Now: $3.19
$3.53
50-Day Range
$2.67
MA: $3.70
$4.97
52-Week Range
$2.50
Now: $3.19
$6.39
Volume785,100 shs
Average Volume1.06 million shs
Market Capitalization$134.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Read More
Paratek Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PRTK
Previous SymbolNASDAQ:TSPT
CUSIP89354M10
Phone617-807-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.54 million
Book Value($1.19) per share

Profitability

Net Income$-128,790,000.00
Net Margins-778.47%

Miscellaneous

Employees101
Market Cap$134.68 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.


Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

How has Paratek Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has decreased by 18.0% and is now trading at $3.19. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Paratek Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Paratek Pharmaceuticals.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Paratek Pharmaceuticals.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) announced its quarterly earnings results on Tuesday, February, 25th. The specialty pharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.03) by $0.22. The specialty pharmaceutical company had revenue of $8.97 million for the quarter, compared to analysts' expectations of $4.78 million. Paratek Pharmaceuticals had a negative return on equity of 5,327.73% and a negative net margin of 778.47%. View Paratek Pharmaceuticals' earnings history.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $68.08 million.

What price target have analysts set for PRTK?

7 Wall Street analysts have issued 12 month price targets for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they expect Paratek Pharmaceuticals' stock price to reach $17.20 in the next year. This suggests a possible upside of 439.2% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals.

Has Paratek Pharmaceuticals been receiving favorable news coverage?

Media coverage about PRTK stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutParatek Pharmaceuticals.

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Verastem (VSTM), EXACT Sciences (EXAS), Exelixis (EXEL), Energy Transfer LP Unit (ET), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Amarin (AMRN).

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Bigham, Chairman & CEO (Age 61)
  • Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 57)
  • Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)
  • Mr. Douglas W. Pagán, Consultant (Age 47)

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (2.04%), General American Investors Co. Inc. (1.94%), ICM Asset Management Inc. WA (1.35%), Water Island Capital LLC (1.26%), Goldman Sachs Group Inc. (1.03%) and Roumell Asset Management LLC (1.02%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel. View institutional ownership trends for Paratek Pharmaceuticals.

Which major investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including Roumell Asset Management LLC, General American Investors Co. Inc., J. Goldman & Co LP, Trellus Management Company LLC, Water Island Capital LLC, Nuveen Asset Management LLC, and Raymond James & Associates. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Randall B Brenner, and William M Haskel. View insider buying and selling activity for Paratek Pharmaceuticals.

Which major investors are buying Paratek Pharmaceuticals stock?

PRTK stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Goldman Sachs Group Inc., ICM Asset Management Inc. WA, Smith Asset Management Group LP, Banco Bilbao Vizcaya Argentaria S.A., Stifel Financial Corp, Oxford Asset Management LLP, and Marshall Wace LLP. View insider buying and selling activity for Paratek Pharmaceuticals.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $3.19.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $134.68 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe. View additional information about Paratek Pharmaceuticals.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is http://www.paratekpharma.com/.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]


MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  406 (Vote Outperform)
Underperform Votes:  364 (Vote Underperform)
Total Votes:  770
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel